Why the study?
What are the bleeding and thrombotic risks associated with antithrombotic strategies in pregnant women with Fontan physiology?
What are the bleeding and thrombotic risks associated with antithrombotic strategies in pregnant women with Fontan physiology?
Antithrombotic therapy in pregnant women with Fontan physiology carries a high bleeding risk (>30%), highlighting the need for individualized, risk-adjusted management.
Answers are grounded in this paper and cite their sources.
Bleeding risk >30% warrants caution with antithrombotic use in pregnant Fontan patients; leaves optimal regimens open for prospective trials.
Current antithrombotic strategies appear effective at attenuating thrombotic risk in pregnant women with a Fontan. However, this comes with high (>30%) bleeding risk, of which 13% are life threatening. Achieving haemostatic balance is challenging in pregnant women with a Fontan, necessitating individualised risk-adjusted counselling and therapeutic approaches that are monitored during the course of pregnancy.
No takes yet. Share an insight, caveat, or question.
Girnius et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: